Literature DB >> 19965957

Pig-a mutation: kinetics in rat erythrocytes following exposure to five prototypical mutagens.

Souk Phonethepswath1, Dean Franklin, Dorothea K Torous, Steven M Bryce, Jeffrey C Bemis, Sarojini Raja, Svetlana Avlasevich, Pamela Weller, Ollivier Hyrien, James Palis, James T Macgregor, Stephen D Dertinger.   

Abstract

An in vivo mutation assay has been developed based on flow cytometric enumeration of glycosylphosphatidylinositol (GPI) anchor-deficient rat erythrocytes. With this method, blood is incubated with anti-CD59-PE and SYTO 13 dye, and flow cytometry is used to score the frequency of CD59-negative erythrocytes. The experiments described herein were designed to define the kinetics of mutant erythrocyte appearance and disappearance from peripheral blood to support appropriate treatment and sampling designs for the assay. Wistar Han rats were treated with one of five prototypical mutagens: N-ethyl-N-nitrosourea (ENU); 7,12-dimethyl-1,2-benz[a]anthracene (DMBA); 4-nitroquinoline-1-oxide; benzo[a]pyrene; and N-methyl-N-nitrosourea. ENU and DMBA were also evaluated in Sprague Dawley rats. Animals were treated on three consecutive days (days 1-3) via oral gavage, and blood specimens were obtained on days -1, 4, 15, 30, 45, and 90 (and day 180 for ENU). A second endpoint of genotoxicity, the frequency of peripheral blood micronucleated reticulocytes, was measured on day 4. Each chemical induced micronuclei and the GPI anchor-deficient phenotype. Increased mutant cell frequencies were evident at day 15. Mutant reticulocyte frequencies remained relatively stable for some chemicals, but others peaked and then dropped significantly. The differences in kinetics observed are presumably related to the degree to which mutation occurs in hematopoietic stem cells versus more committed cells with limited self-renewal capacity. Collectively, the results suggest that enumerating GPI anchor-deficient erythrocytes is an efficient means of evaluating the in vivo mutagenic potential of chemicals. The kinetics and ease of scoring this blood-based endpoint suggest that integration into routine toxicology studies will be feasible.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965957      PMCID: PMC2902916          DOI: 10.1093/toxsci/kfp289

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  27 in total

1.  Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals.

Authors:  D J Araten; K Nafa; K Pakdeesuwan; L Luzzatto
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Quantitative analysis of the expression of glycosylphosphatidylinositol-anchored proteins during the maturation of different hematopoietic cell compartments of normal bone marrow.

Authors:  Pilar María Hernández-Campo; Julia Almeida; Sergio Matarraz; María de Santiago; María Luz Sánchez; Alberto Orfao
Journal:  Cytometry B Clin Cytom       Date:  2007-01-15       Impact factor: 3.058

Review 3.  Leukemic stem cells: where do they come from?

Authors:  Emmanuelle Passegué; Irving L Weisman
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

4.  Flow cytometric analysis of micronuclei in peripheral blood reticulocytes: II. An efficient method of monitoring chromosomal damage in the rat.

Authors:  James T MacGregor; Michelle E Bishop; James P McNamee; Makoto Hayashi; Norhide Asano; Akihiro Wakata; Madoka Nakajima; Junichiro Saito; Anane Aidoo; Martha M Moore; Stephen D Dertinger
Journal:  Toxicol Sci       Date:  2006-08-03       Impact factor: 4.849

5.  The spectrum of somatic mutations in the PIG-A gene in paroxysmal nocturnal hemoglobinuria includes large deletions and small duplications.

Authors:  K Nafa; M Bessler; H Castro-Malaspina; S Jhanwar; L Luzzatto
Journal:  Blood Cells Mol Dis       Date:  1998-09       Impact factor: 3.039

Review 6.  Cancer stem cells: models and concepts.

Authors:  Piero Dalerba; Robert W Cho; Michael F Clarke
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

7.  In vivo mutation assay based on the endogenous Pig-a locus.

Authors:  Steven M Bryce; Jeffrey C Bemis; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2008-05       Impact factor: 3.216

8.  Development of an in vivo gene mutation assay using the endogenous Pig-A gene: I. Flow cytometric detection of CD59-negative peripheral red blood cells and CD48-negative spleen T-cells from the rat.

Authors:  Daishiro Miura; Vasily N Dobrovolsky; Yoshinori Kasahara; Yasuhiro Katsuura; Robert H Heflich
Journal:  Environ Mol Mutagen       Date:  2008-10       Impact factor: 3.216

9.  Development of an in vivo gene mutation assay using the endogenous Pig-A gene: II. Selection of Pig-A mutant rat spleen T-cells with proaerolysin and sequencing Pig-A cDNA from the mutants.

Authors:  Daishiro Miura; Vasily N Dobrovolsky; Roberta A Mittelstaedt; Yoshinori Kasahara; Yasuhiro Katsuura; Robert H Heflich
Journal:  Environ Mol Mutagen       Date:  2008-10       Impact factor: 3.216

10.  Erythrocyte-based Pig-a gene mutation assay: demonstration of cross-species potential.

Authors:  Souk Phonethepswath; Steven M Bryce; Jeffrey C Bemis; Stephen D Dertinger
Journal:  Mutat Res       Date:  2008-08-26       Impact factor: 2.433

View more
  16 in total

1.  When pigs fly: immunomagnetic separation facilitates rapid determination of Pig-a mutant frequency by flow cytometric analysis.

Authors:  Stephen D Dertinger; Steven M Bryce; Souk Phonethepswath; Svetlana L Avlasevich
Journal:  Mutat Res       Date:  2011-01-28       Impact factor: 2.433

2.  Rat Pig-a mutation assay responds to the genotoxic carcinogen ethyl carbamate but not the non-genotoxic carcinogen methyl carbamate.

Authors:  Jeffrey C Bemis; Carson Labash; Svetlana L Avlasevich; Kristine Carlson; Ariel Berg; Dorothea K Torous; Matthew Barragato; James T MacGregor; Stephen D Dertinger
Journal:  Mutagenesis       Date:  2015-04-01       Impact factor: 3.000

3.  Comparison of male versus female responses in the Pig-a mutation assay.

Authors:  Carson Labash; Svetlana L Avlasevich; Kristine Carlson; Dorothea K Torous; Ariel Berg; Jeffrey C Bemis; James T MacGregor; Stephen D Dertinger
Journal:  Mutagenesis       Date:  2015-04-01       Impact factor: 3.000

4.  Integration of Pig-a, micronucleus, chromosome aberration and comet assay endpoints in a 28-day rodent toxicity study with urethane.

Authors:  Leon F Stankowski; Marilyn J Aardema; Timothy E Lawlor; Kamala Pant; Shambhu Roy; Yong Xu; Reem Elbekai
Journal:  Mutagenesis       Date:  2015-05-01       Impact factor: 3.000

5.  Pig-a gene mutation assay study design: critical assessment of 3- versus 28-day repeat-dose treatment schedules.

Authors:  Azeddine Elhajouji; Tamsanqa Tafara Hove; Oliver O'Connell; Hansjoerg Martus; Stephen D Dertinger
Journal:  Mutagenesis       Date:  2020-09-12       Impact factor: 3.000

6.  Defining EMS and ENU dose-response relationships using the Pig-a mutation assay in rats.

Authors:  Krista L Dobo; Ronald D Fiedler; William C Gunther; Catherine J Thiffeault; Zoryana Cammerer; Stephanie L Coffing; Thomas Shutsky; Maik Schuler
Journal:  Mutat Res       Date:  2011-06-24       Impact factor: 2.433

7.  In vivo pig-a and micronucleus study of the prototypical aneugen vinblastine sulfate.

Authors:  Svetlana L Avlasevich; Carson Labash; Dorothea K Torous; Jeffrey C Bemis; James T MacGregor; Stephen D Dertinger
Journal:  Environ Mol Mutagen       Date:  2017-08-19       Impact factor: 3.216

8.  Integration of mutation and chromosomal damage endpoints into 28-day repeat dose toxicology studies.

Authors:  Stephen D Dertinger; Souk Phonethepswath; Dean Franklin; Pamela Weller; Dorothea K Torous; Steven M Bryce; Svetlana Avlasevich; Jeffrey C Bemis; Ollivier Hyrien; James Palis; James T MacGregor
Journal:  Toxicol Sci       Date:  2010-03-04       Impact factor: 4.849

9.  Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapy.

Authors:  Stephen D Dertinger; Svetlana L Avlasevich; Dorothea K Torous; Jeffrey C Bemis; Souk Phonethepswath; Carson Labash; Kristine Carlson; Jared Mereness; John Cottom; James Palis; James T MacGregor
Journal:  Toxicol Sci       Date:  2014-05-05       Impact factor: 4.849

10.  Dextran sulfate sodium mouse model of inflammatory bowel disease evaluated for systemic genotoxicity via blood micronucleus and Pig-a gene mutation assays.

Authors:  Christopher Kirby; Ayesha Baig; Svetlana L Avlasevich; Dorothea K Torous; Shuchang Tian; Priyanka Singh; Jeffrey C Bemis; Lawrence J Saubermann; Stephen D Dertinger
Journal:  Mutagenesis       Date:  2020-03-27       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.